Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Allergic Asthma Age: Adult Condition: Pre-treatment serum IgE levels greater than 30-100 IU/mL |
Dose: Subcutaneous – 150 mg Frequency: every 4 weeks Note: Doses no more than 150 mg should be administered at 1 injection site. |
|
Indication: Allergic Asthma Age: Adult Condition: Pre-treatment serum IgE levels greater than 30-100 IU/mL |
Dose: Subcutaneous – 300 mg Frequency: every 4 weeks Note: Doses no more than 150 mg should be administered at 1 injection site. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Allergic Asthma Age: less than 6 years |
Dose: Subcutaneous – Safety and efficacy not established Note: moderate-to-severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids |
|
Indication: Allergic Asthma Age: 6 to less than 12 years |
Dose: Subcutaneous – 75-375 mg Frequency: every 2-4 weeks Note: moderate-to-severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids; Determine precise dose and frequency by total IgE level and body weight measured before starting therapy and then periodically |
Administration
- For subcutaneous injection only
- Each injection takes 5-10 seconds
Side Effect
- Asthma (aged More than 12 yr)
- Injection site reactions (45%)
- CIU
- Headache (12%)
- Asthma (aged More than 12 yr)
- Arthralgia (8%)
- Pain (7%)
- Leg pain (4%)
- Dizziness (3%)
- Fatigue (3%)
- Earache (2%)
- Pruritus (2%)
- Dermatitis (2%)
- Arm pain (2%)
- Fracture (2%)
- CIU
- Nasopharyngitis (9.1%)
- Arthralgia (2.9%)
- Viral Upper respiratory tract infection (URTI) (2.3%)
- Nausea (1.1%)
- Cough (1.1%)
- Sinusitis (1.1%)
- Upper respiratory tract infection (URTI) (1.1%)
- Nasal polyps
- Headache (8.1%)
- Injection site reactions (5.2%)
- Upper abdominal pain (3%)
- Arthralgia (3%)
- Dizziness (3%)
- Anaphylactic reactions including bronchospasm
- hypotension
- syncope
- dyspnoea and/or angioedema of the throat or tongue
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No formal drug or vaccine interaction studies have been performed
|
-
|
|
Inhaled and oral Corticosteroids (Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone), inhaled short- and long-acting beta-agonists, leukotriene modifiers, theophyllines, oral Antihistamines (Diphenhydramine, Loratadine, Levocetirizine, Cetirizine, Fexofenadine, Hydroxyzine, Bilastin)
|
No indication that the safety of Omalizumab was altered with these commonly used asthma medications
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Previous severe hypersensitivity
|
Risk of anaphylaxis
|
|
Status asthmaticus
|
May worsen acute condition
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store between 2-8°C. May be transferred at room temp. Do not freeze. Following reconstitution, protect from direct sunlight. Stable for up to 8 hr if refrigerated or 4 hr if at room temp.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.